• 5669 Citations
  • 46 h-Index
1988 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Dr. Junxuan "Johnny" Lu's research interests and expertise include angiogenesis, apoptosis, autophagy, cell cycle regulation, senescence, prostate and mammary carcinogenesis models, androgen and estrogen receptor signaling; Proteomics-iTRAQ; transcriptomics; metabolomics; PK/PD; biomarkers; immunity and cancer; and clinical translation research.

The major areas of ongoing studies in the Lu lab include: 

  • Herbal compounds as novel cancer chemopreventive and therapeutic agents. The Lu lab faculty and associates discovered pyranocoumarins from Korean angelica as a novel class of anti-androgens. They are studying Korean angelica extract and compounds for anti-cancer efficacy and mechanisms using xenograft and transgenic models. They are planning clinical trials in prostate cancer patients with oncologists and urologists at Penn State Cancer Institute. 
  • Next-gen selenium compounds for cancer chemoprevention. The Lu lab has used cell culture models (cancer, vascular endothelial cells) to identify the lead Se compounds with cancer chemopreventive potential and their cellular and molecular mechanisms. They assess in vivo efficacy in animal models including xenografts, transgenic and conditional knockout mice models. The Lu lab collaborates with chemist colleagues in the department to study novel selenium hybrid drugs. 
  • Precision therapy of cancer. The Lu lab has contributed to the findings that hexokinase 2 (HK2) plays a crucial role in subsets of aggressive prostate cancer and the proof of principle that co-targeting HK2-mediated Warburg effect with 2-deoxyglucose and its ULK1-mediated anti-apoptotic autophagy with chloroquine remarkably regresses these cancers in mouse models. The lab is collaborating with oncologists to repurpose these drugs to cancer patients.

Fingerprint Dive into the research topics where Junxuan Lu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

ROLE RAS/MAPK PATHWY IN MAM CANC PROMOT BY LINOLEIC ACID

Lu, J.

5/16/974/30/98

Project: Research project

Research Output

The Impact of One-week Dietary Supplementation with Kava on Biomarkers of Tobacco Use and Nitrosamine-based Carcinogenesis Risk among Active Smokers

Wang, Y., Narayanapillai, S. C., Tessier, K. M., Strayer, L. G., Upadhyaya, P., Hu, Q., Kingston, R., Salloum, R. G., Lu, J., Hecht, S. S., Hatsukami, D. K., Fujioka, N. & Xing, C., May 1 2020, In : Cancer prevention research (Philadelphia, Pa.). 13, 5, p. 483-492 10 p.

Research output: Contribution to journalArticle

  • Optimizing live-animal bioluminescence imaging prediction of tumor burden in human prostate cancer xenograft models in SCID-NSG mice

    Kim, S., Zhang, Y., Tang, S., Qin, C., Karelia, D., Sharma, A., Jiang, C. & Lu, J., Jun 15 2019, In : Prostate. 79, 9, p. 949-960 12 p.

    Research output: Contribution to journalArticle

  • 5 Scopus citations

    Role of p53-senescence induction in suppression of LNCaP prostate cancer growth by cardiotonic compound bufalin

    Zhang, Y., Dong, Y., Melkus, M. W., Yin, S., Tang, S. N., Jiang, P., Pramanik, K., Wu, W., Kim, S., Ye, M., Hu, H., Lu, J. & Jiang, C., Nov 2018, In : Molecular cancer therapeutics. 17, 11, p. 2341-2352 12 p.

    Research output: Contribution to journalArticle

  • 5 Scopus citations

    Prostate Cancer Xenograft Inhibitory Activity and Pharmacokinetics of Decursinol, a Metabolite of Angelica gigas Pyranocoumarins, in Mouse Models

    Wu, W., Tang, S. N., Zhang, Y., Puppala, M., Cooper, T. K., Xing, C., Jiang, C. & Lü, J., Jan 1 2017, In : American Journal of Chinese Medicine. 45, 8, p. 1773-1792 20 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations